Biopharma Firm Veru Plunges Following Equity Offering Announcement

Shares of Veru experienced severe volatility after the company revealed plans to raise capital through a public securities offering. The biopharmaceutical company’s proposal to issue common stock alongside Series A and Series B convertible notes triggered an immediate sell-off among concerned investors.

The financial markets responded swiftly to Veru’s capital raising plans. During the latest trading session, the company’s stock price collapsed by 3.29 percent to settle at $3.53, having opened at $3.67. The trading range proved even more dramatic, spanning a full 7.00 percent between $3.50 and $3.745.

This recent decline represents just part of a broader downward trend. Over seven of the past ten trading days, Veru shares have recorded losses, Read more...